Please login to the form below

Not currently logged in

FDA set to publish reviews of data relating to COVID-19 vaccine EUAs

Agency set to publish data as part of 'transparency' efforts

The US Food and Drug Administration (FDA) has announced that it will publicly post reviews of data relating to emergency use authorisations (EUA) of COVID-19 vaccines.

In a statement, FDA commissioner Stephen Hahn revealed the transparency plans, adding that the agency’s drug and biological products center will publish its reviews ‘to the extent appropriate and permitted by law’.

“Let me be clear on a crucial point – the issuance of an EUA is based on data and science. For an EUA to be authorised, FDA’s career scientists conduct a rigorous evaluation of currently available scientific evidence about a medical product,” said Hahn

“We work with sponsors so that additional data about the product’s safety and effectiveness continues to be collected and reviewed,” he added.

In October, the FDA released new guidelines detailing how it will grant EUAs for COVID-19 vaccines, which included a new advisory stipulating that data from phase 3 studies should include a median follow-up duration of at least two months.

Following this guidance, Bloomberg reported that the FDA will also not require pre-approval inspections for vaccine developers seeking EUAs.

Jerry Weir, director of viral products at the FDA’s vaccines office, revealed that companies who submit their COVID-19 vaccine for an EUA will not have to undergo these inspections during an FDA advisory committee meeting.

Weir did add that all companies that submit a potential COVID-19 vaccine for an EUA will be required to provide complete details of their manufacturing processes and demonstrate how they have established a quality control unit.

A number of potential vaccines are involved in late-stage clinical testing, and Pfizer/BioNTech and Moderna have both reported initial efficacy data on their vaccine candidates this month.

Pfizer/BioNTech’s COVID-19 vaccine candidate, BNT162b2, demonstrated an efficacy rate of above 90% in preliminary results from a phase 3 study that was published last week.

On Monday, Moderna also revealed the first results for its vaccine, mRNA-1273, reporting that the vaccine candidate achieved an efficacy rate of 94.5% in its phase 3 study.

The respective vaccine developers did add, however, that this efficacy rate could change over the course of ongoing evaluations.

Article by
Lucy Parsons

18th November 2020

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....